Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
XENE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.74 - $46.00
Previous CloseN/A
Volume41.45K
Average Volume (3M)874.46K
Market Cap
$2.87B
Enterprise Value$1.99B
Total Cash (Recent Filing)$487.55M
Total Debt (Recent Filing)$8.71M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 05, 2025EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding77,105,800
10 Day Avg. Volume631,979
30 Day Avg. Volume874,463
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue198.92
Enterprise Value/Gross Profit267.19
Enterprise Value/Ebitda-6.30
Forecast
1Y Price Target
$53.33Price Target Upside47.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe company announced the completion of patient recruitment in X-TOLE2 and reaffirmed its guide for top-line data in early 2026, which should be received positively by investors.
Financial PositionThe company ended the quarter with approximately $625 million in cash, which management believes should fund operations into 2027.
Market PositionAzetukalner is the leading novel therapy candidate for focal epilepsy, and data from the X-TOLE and X-TOLE2 studies are sufficient for NDA submission in 2026.
Bears Say
CompetitionPotential competition from BioHaven Pharmaceuticals with its Kv7 channel modulator, BHV-7000, which is expected to readout results in focal onset epilepsy.
Investment RequirementsFurther investment and patience are required for azetukalner, despite its strong Phase 2b data and differentiated mechanism.
Regulatory ChallengesXENE will refine timelines for trial results once the trial's last patient has been randomized.
Xenon News
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $26.74 and its highest was $46.00 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $2.87B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Nov 05, 2025 which is in 52 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Aug 11, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.987 by -$0.083.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -1.15.
How many shares outstanding does Xenon have?
Xenon has 77,105,800 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.987. Following the earnings report the stock price went up 5.512%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
Xenon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.33 (47.28% Upside)
$53.33 (47.28% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 113.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.02%
12-Months-Change
Fundamentals
Return on Equity
-37.65%
Trailing 12-Months
Asset Growth
-23.72%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals Inc. (XENE) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to improve the lives of patients with neurological disorders. The company primarily operates in the pharmaceutical and biotechnology sectors, leveraging its proprietary ion channel neurology platform to advance its pipeline of novel therapeutics. Xenon's core products include a range of investigational drugs targeting various neurological conditions, including epilepsy and pain disorders.
XENE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Xenon Pharmaceuticals, with significant progress in their epilepsy and neuropsychiatric programs, strong financial health, and promising early-stage pipeline developments. However, there are some uncertainties in the bipolar depression program and regulatory filing timeline. Overall, the positive advancements strongly outweigh the noted uncertainties.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$53.33
▲(47.28% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Scholar Rock Holding
―
Immunovant
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
0.14% Insiders
29.82% Mutual Funds
57.28% Other Institutional Investors
6.69% Public Companies and
Individual Investors